IDSA News - January 2014  (Plain Text Version)

Return to Graphical Version


In this issue:
Patient Care and Science
•  FDA Approves Simeprevir and Sofosbuvir for Chronic Hepatitis C
Policy and Advocacy
•  Congress Approves Partial Relief from Sequestration Funding Cuts
•  IDSA Supports Diagnostics Bill Moving through House of Representatives
•  IDSA and PIDS Submit Comments to FDA on Proposed Drug Shortage Rule
•  Congressional Briefing Highlights Barriers to Immunization for Older Adults
•  IDSA, SHEA, PIDS Call for Mandatory Immunization of Health Care Personnel
•  HIVMA Welcomes HIV Policy Assessment Directive in Defense Bill
•  President Obama Mentions Vaccines and Drug Resistance in State of the Union
Clinical Practice Management
•  New Resource Helps ID Specialists Prove Their Value
•  President Obama Signs Bill to Prevent Scheduled Medicare Cut
Science Speaks Blog
•  The Center for Global Health Policy Examines the Impact of Drug Prices on Vulnerable Populations, and Other Newsworthy Events
You and Your Colleagues
•  Renew Dues and Update Your Membership
•  Members on the Move
•  New Members
•  In Memoriam: Martin C. McHenry, MD, MS, FIDSA (1932-2013)
Education and Resources
•  Free Online Course on Antimicrobial Stewardship
•  Changes to ABIM MOC Now In Effect
•  Open Forum Infectious Diseases Now Accepting Submissions
•  Apply Now for the ID Research Careers Meeting
Top Story
•  From the President: New Website Provides Clinicians with Timely Advice on HCV
•  ADAPT Act Would Promote New Drug Development
•  Updated Guideline for Vaccination of Immunocompromised Host Now Available
•  IDSA Journal Club


FDA Approves Simeprevir and Sofosbuvir for Chronic Hepatitis C

In recent weeks the U.S. Food and Drug Administration (FDA) has approved sofosbuvir (Sovaldi) and simeprevir (Olysio) to treat chronic hepatitis C virus (HCV) infection. Sofosbuvir is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon.  
IDSA offers two email services to help members stay informed of new drug approvals and similar updates from FDA and the Centers for Disease Control and Prevention (CDC). Content includes a range of topics, including drug warnings, recalls, and outbreak investigations. Recent alerts have included:
Avian Influenza A (H5N1) Virus (1/15/2014, Canadian cases)
Early Reports of pH1N1-Associated Illnesses for the 2013-14 Influenza Season Summary (1/7/2014)
Abrams Royal Pharmacy Issues Voluntary Nationwide Recall of All Lots of Unexpired Sterile Products Due to Lack of Sterility Assurance (12/19/2013)
IDSA members can sign up for these services online. (To subscribe, check the appropriate boxes to receive CDC’s Health Alert Network (HAN) messages and/or alerts from FDA, and provide your email address and name where indicated.)
For more information about the new hepatitis drugs and evolving clinical recommendations from IDSA and liver disease experts, see

Is Your Facility Experiencing Antibiotic Shortages?

IDSA members are urged to report drug shortages directly to FDA and to copy IDSA staff at